tradingkey.logo

Nexalin Technology Inc

NXL
View Detailed Chart
0.515USD
-0.105-16.95%
Close 02/06, 16:00ETQuotes delayed by 15 min
9.37MMarket Cap
LossP/E TTM

Nexalin Technology Inc

0.515
-0.105-16.95%
Intraday
1m
30m
1h
D
W
M
D

Today

-16.95%

5 Days

-9.67%

1 Month

-32.46%

6 Months

-47.99%

Year to Date

-7.72%

1 Year

-86.01%

View Detailed Chart

Key Insights

Nexalin Technology Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 116 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nexalin Technology Inc's Score

Industry at a Glance

Industry Ranking
116 / 205
Overall Ranking
300 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Nexalin Technology Inc Highlights

StrengthsRisks
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Growing
The company is in a growing phase, with the latest annual income totaling USD 168.72K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 168.72K.
Overvalued
The company’s latest PE is -0.80, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 722.74K shares, decreasing 52.01% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 177.92K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.05.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
4.000
Target Price
+545.16%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Nexalin Technology Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Nexalin Technology Inc Info

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Ticker SymbolNXL
CompanyNexalin Technology Inc
CEOWhite (Mark)
Websitehttps://nexalin.com
KeyAI